New Pancreatic Cancer Drug Daraxonrasib Extends Survival, Offers Hope
Daraxonrasib, a new drug, nearly doubled survival for advanced pancreatic cancer patients in a trial, extending life by 6+ months with fewer side effects than chemo. Hailed as a 'crowning achievement,' it opens new research avenues, though it's not a cure.